Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services;
H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.
Duration: March 4, 2009
to
present
General Issues: Health Issues , Taxation/Internal Revenue Code , Defense , Medical/Disease Research/Clinical Labs
Spending: about $4,870,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: U.S. Senate, House of Representatives, U.S. Senate,, Office of Management & Budget (OMB)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on April 22.
Original Filing: 301571673.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services;
H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Section 201 of H.R. 7024, the Tax Relief for American Families and Workers Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on Jan. 22.
Original Filing: 301537162.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), and Section 502 of H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services;
A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions;
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 866, the American Innovation and Jobs Act, and H.R. 2673, the American Innovation and R & D Competitiveness Act, provisions relating to immediate deductibility of research and development expenses under Internal Revenue Code Section 174.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511759.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; H.R. 3791, the Improving DATA in Public Health Act, Section 107 of H.R. 4420, the Preparedness and Response Authorization Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories; H.R. 3248, the Diagnostic Lab Testing Transparency Act, Section 101 of H.R. 4822, the Health Care Price Transparency Act, Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on July 20, 2023.
Original Filing: 301487731.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 3791, the Improving DATA in Public Health Act, and H.R. 3742, a bill to direct a GAO study to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies, provisions relating to demographic data reporting obligations for laboratories;
H.R. 3248, the Diagnostic Lab Testing Transparency Act, and Section 105 of H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, provisions relating to publication of rates for laboratory services;
Federal policy related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI);
Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on April 20, 2023.
Original Filing: 301461280.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2024 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on Jan. 20, 2023.
Original Filing: 301440462.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests; H.R. 4040, the Advancing Telehealth Beyond COVID-19 Act, H.R. 6202, the Telehealth Extension Act, and H.R. 7573/S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests; H.R. 8152, the American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy; S. 3799, the PREVENT Pandemics Act, provisions relating to demographic data reporting obligations for laboratories; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on Oct. 20, 2022.
Original Filing: 301416627.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests;
H.R. 4040, the Advancing Telehealth Beyond COVID-19 Act, H.R. 6202, the Telehealth Extension Act, and H.R. 7573/S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests;
H.R. 8152, the American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy;
S. 3799, the PREVENT Pandemics Act, provisions relating to demographic data reporting obligations for laboratories;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and
Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on July 20, 2022.
Original Filing: 301392973.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests;
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing;H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on April 20, 2022.
Original Filing: 301370735.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories;
Federal policy related to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding;
H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing;
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on Jan. 20, 2022.
Original Filing: 301334222.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
S. 610, the Protecting Medicare and American Farmers from Sequester Cuts Act, provisions relating to delays in data collection and rate changes pertinent to the Medicare Clinical Laboratory Fee Schedule, mitigation of the Medicare sequester and rate changes pertinent to the Medicare Physician Fee Schedule, and suspension of certain statutory pay-as-you-go requirements;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; and
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing,
S. 1605, the National Defense Authorization Act for Fiscal Year 2022, provisions relating to TRICARE coverage of preconception and prenatal carrier screening;
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313019.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; and
Federal policy relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing, including a discussion draft of the Cures 2.0 Act;
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on July 20, 2021.
Original Filing: 301290017.xml
Lobbying Issues
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93;
Federal policy relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing, including a discussion draft of the Cures 2.0 Act;
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $110,000. The report was filed on April 20, 2021.
Original Filing: 301267701.xml
Lobbying Issues
Legislation relating to FDA oversight of laboratory-developed test;
Federal policy related to implementation of Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing;
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; and
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $100,000. The report was filed on Jan. 20, 2021.
Original Filing: 301242356.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;
Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing;
H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time;
Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation;
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill; and
Title I of Division BB of the Consolidated Appropriations Act of 2021, Pub. L. 116-260, provisions relating to surprise billing.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $100,000. The report was filed on Oct. 20, 2020.
Original Filing: 301223180.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy related to implementation of the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;
H.R. 7059, the Coronavirus Provider Protection Act and H.R. 7528, the Get America Back to Work Act, provisions relating to limitation of liability for COVID-19 related services;
Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing;
Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $100,000. The report was filed on July 20, 2020.
Original Filing: 301202205.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
H.R. 266, the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured;
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on April 20, 2020.
Original Filing: 301180121.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
Federal policy relating to FDA oversight of pharmacogenetic tests, including potential inclusion in the Fiscal Year 2021 Agriculture-FDA appropriations bill;
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, funding for child care for laboratory personnel, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed;
H.R. 3584/ S. 3049, the Laboratory Access for Beneficiaries (LAB) Act, provisions relating to modification of reporting of private-sector payments used to establish Medicare rates for clinical diagnostic laboratory tests and directing a third party study and report including recommendations on private-sector payment data collection requirements and Medicare rate methodologies.
H.R. 1865, the Further Consolidated Appropriations Act, Section 105 of Division N, provisions incorporating the LAB Act;
Federal policy relating to drug development; and
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220) including potential inclusion in the Fiscal Year 2021 Labor-HHS appropriations bill.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Jan. 21, 2020.
Original Filing: 301129131.xml
Lobbying Issues
Healthcare issues related to clinical laboratories;
FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act;
H.R. 3584/ S. 3049, the Laboratory Access for Beneficiaries (LAB) Act, provisions relating to modification of reporting of private-sector payments used to establish Medicare rates for clinical diagnostic laboratory tests and directing a third party study and report including recommendations on private-sector payment data collection requirements and Medicare rate methodologies.
H.R. 1865, the Further Consolidated Appropriations Act, Section 105 of Division N, provisions incorporating the LAB Act;
Federal policy relating to drug development; and
Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078832.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule including provisions contained in H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act ; federal policy relating to drug development; federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); federal policy relating to subject matter eligibility for patents of laboratory tests.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on July 22, 2019.
Original Filing: 301058812.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule including provisions contained in H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act ; federal policy relating to drug development; federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); federal policy relating to subject matter eligibility for patents of laboratory tests.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on April 22, 2019.
Original Filing: 301038288.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Jan. 22, 2019.
Original Filing: 301017782.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA), FDAs technical assistance on DAIA, and the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Oct. 22, 2018.
Original Filing: 300998491.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; and federal policy relating to drug development.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on July 20, 2018.
Original Filing: 300978263.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; and federal policy relating to drug development.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $80,000. The report was filed on April 20, 2018.
Original Filing: 300956024.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; federal policy relating to drug development; and TRICARE.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $80,000. The report was filed on Jan. 22, 2018.
Original Filing: 300937560.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; federal policy relating to drug development; and TRICARE.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Oct. 20, 2017.
Original Filing: 300916438.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; federal policy relating to drug development; and TRICARE.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $80,000. The report was filed on July 20, 2017.
Original Filing: 300896258.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; federal policy relating to drug development; and TRICARE.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300877511.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; federal policy relating to drug development; and TRICARE.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856647.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; and federal policy relating to drug development.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $80,000. The report was filed on Oct. 19, 2016.
Original Filing: 300832323.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; and federal policy relating to drug development.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $80,000. The report was filed on July 20, 2016.
Original Filing: 300820966.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on April 20, 2016.
Original Filing: 300802670.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $80,000. The report was filed on Jan. 20, 2016.
Original Filing: 300782286.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $70,000. The report was filed on Oct. 20, 2015.
Original Filing: 300764269.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300745871.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $70,000. The report was filed on April 20, 2015.
Original Filing: 300727153.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $60,000. The report was filed on Jan. 20, 2015.
Original Filing: 300706931.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to TRICARE reimbursement for molecular pathology testing
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $60,000. The report was filed on Oct. 20, 2014.
Original Filing: 300687822.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to TRICARE reimbursement for molecular pathology testing
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $70,000. The report was filed on July 21, 2014.
Original Filing: 300668541.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to TRICARE reimbursement for molecular pathology testing
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on April 21, 2014.
Original Filing: 300648368.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; HR 2914, the Promoting Integrity in Medicare Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to TRICARE reimbursement for molecular pathology testing
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $60,000. The report was filed on Jan. 22, 2014.
Original Filing: 300628401.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; HR 2914, the Promoting Integrity in Medicare Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to TRICARE reimbursement for molecular pathology testing
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $60,000. The report was filed on Oct. 21, 2013.
Original Filing: 300607172.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on July 22, 2013.
Original Filing: 300585553.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on April 22, 2013.
Original Filing: 300559971.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests; Medicare reimbursement levels for laboratory services
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on Jan. 22, 2013.
Original Filing: 300541461.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests and related legislation (H.R. 3207); Medicare reimbursement levels for laboratory services
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on Oct. 22, 2012.
Original Filing: 300517782.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests and related legislation (H.R. 3207); Medicare reimbursement levels for laboratory services
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on July 20, 2012.
Original Filing: 300496298.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests and related legislation (H.R. 3207); Medicare reimbursement levels for laboratory services
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on April 20, 2012.
Original Filing: 300469362.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests and related legislation (H.R. 3207); Medicare reimbursement levels for laboratory services (including H.R. 3630, the Middle Class Tax Relief and Job Creation Act) and potential beneficiary cost-sharing requirements
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $40,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445812.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests and related legislation (H.R. 3207); Medicare reimbursement levels for laboratory services and potential beneficiary cost-sharing requirements
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300422912.xml
Lobbying Issues
Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests and draft legislation; Medicare reimbursement levels for laboratory services and potential beneficiary cost-sharing requirements; closing existing exceptions to in-office ancillary services for physicians in Medicare
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $30,000. The report was filed on July 19, 2011.
Original Filing: 300398388.xml
Lobbying Issues
Health reform law implementation issues related to clinical laboratories; FDA oversight of laboratory developed tests and potential legislation; Medicare reimbursement levels for laboratory services and potential beneficiary cost-sharing requirements; closing existing exceptions to in-office ancillary services for physicians in Medicare
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $30,000. The report was filed on April 26, 2011.
Original Filing: 300381855.xml
Lobbying Issues
Health reform law implementation issues related to clinical labs; FDA oversight of laboratory developed tests and potential legislation; the Centers for Medicare and Medicaid Services (CMS) physician signature issue; closing existing exceptions to in-office ancillary services for physicians in Medicare and CMS drugs of abuse testing
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $30,000. The report was filed on Jan. 25, 2011.
Original Filing: 300356068.xml
Lobbying Issues
Any and all issues related to medical laboratory testing including reimbursement and regulation of clinical laboratory testing services and issues related to personalized medicine; H.R. 4994, the Medicare and Medicaid Extenders' Act of 2010, including extension of payment for technical component of certain pathology services
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Any and all issues related to medical laboratory testing; H.R. 4994, the Medicare and Medicaid Extenders' Act of 2010, including extension of payment for technical component of certain pathology services
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2010
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Oct. 20, 2010.
Original Filing: 300328227.xml
Lobbying Issues
Any and all issues related to medical laboratory testing
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
2nd Quarter, 2010
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on July 20, 2010.
Original Filing: 300295950.xml
Lobbying Issues
Any and all issues related to medical laboratory testing; HR 3590, The Patient Protection and Affordable Care Act; HR 4872, Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Any and all issues related to medical laboratory testing; HR 3590, The Patient Protection and Affordable Care Act; HR 4872, Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2010
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on April 20, 2010.
Original Filing: 300275577.xml
Lobbying Issues
Any and all issues related to medical laboratory testing; HR 3590, The Patient Protection and Affordable Care Act; HR 4872, Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Any and all issues related to medical laboratory testing; HR 3590, The Patient Protection and Affordable Care Act; HR 4872, Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2009
In Q4, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Jan. 20, 2010.
Original Filing: 300247154.xml
Lobbying Issues
Any and all issues related to medical laboratory testing; HR 3200, America's Affordable Health Choices Act of 2009; HR 3590, The Patient Protection and Affordable Care Act; HR 3962, Affordable Health Care for America Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Any and all issues related to medical laboratory testing; HR 3200, America's Affordable Health Choices Act of 2009; HR 3590, The Patient Protection and Affordable Care Act; HR 3962, Affordable Health Care for America Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2009
In Q3, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on Oct. 20, 2009.
Original Filing: 300221898.xml
Lobbying Issues
Any and all issues related to medical laboratory testing, HR 3200, America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Any and all issues related to medical laboratory testing, HR 3200, America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2009
In Q2, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $90,000. The report was filed on July 20, 2009.
Original Filing: 300192970.xml
Lobbying Issues
Any and all issues related to medical laboratory testing, HR 3200, America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Any and all issues related to medical laboratory testing, HR 3200, America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2009
In Q1, Kelley Drye & Warren LLP lobbied for Laboratory Corporation of America Holdings , earning $30,000. The report was filed on April 20, 2009.
Original Filing: 300165278.xml
Lobbying Issues
Any and all issues related to medical laboratory testing
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...